Mutations at Positions 181 and 185 Within the LCMV GP Protein Increase Tumor Cell Infectivity, Limit Induction of Type I Interferon, and Accelerate T Cell Activation
Viruses · 2026
DOI: 10.3390/v18091002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2026. Verfasst von Michael Bergerhausen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Abalos Therapeutics, 40225 Düsseldorf, Germany. Hauptthemen laut MEDLINE: Interferon Type I, Lymphocytic choriomeningitis virus, Lymphocyte Activation, Mutation. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Federal Ministry of Education and Research.
Abstract (Originalsprache)
The lymphocytic choriomeningitis virus (LCMV) represents a strong T cell activating virus with anti-tumoral properties. In recent work, we developed an attenuated cancer cell-adapted reassortant LCMV strain carrying tumor-tropic mutations. The immunological mechanisms underlying these mutations remained unknown. Here, we passaged wild-type LCMV-WE in human lung cancer H1975 cells for 52 passages. After 29 passages, the virus acquired the GP1 mutations I181M and R185W, involved in viral receptor interactions, which remained stable throughout the subsequent 33 passages. Compared with wild-type LCMV-WE, LCMV-P52 showed increased infectivity, partly concomitant with enhanced propagation in human tumor cells. In vivo, LCMV-P52 induced reduced type I interferon (IFN-I) responses and showed accelerated expansion in CD169+ macrophages. Propagation within the splenic marginal zone correlated with accelerated priming of virus-specific CD8+ T cells and limited liver tissue damage. Mechanistic in vitro experiments showed that the I181M and R185W mutations were associated with substantially reduced infection of plasmacytoid dendritic cells (pDCs). Collectively, the I181M and R185W mutations limit systemic IFN-I induction and accelerate LCMV propagation in CD169+ macrophages, correlating with improved CD8+ T cell function and reduced liver damage. These findings provide mechanistic insight into how defined GP mutations can modulate viral tropism and antiviral immune responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Abalos Therapeutics, 40225 Düsseldorf, Germany.
- Institute of Immunology, University Hospital Essen, 45147 Essen, Germany.
- Department of Molecular Medicine II, Medical Faculty, Heinrich Heine University, 40225 Düsseldorf, Germany.
ORCID-Profile: Michael Bergerhausen, Lisa Holnsteiner, Rosa Schmitz
Förderung
- Federal Ministry of Education and Research
Zitieren
APA
Bergerhausen, M., Holnsteiner, L., Friedrich-Becker, S. K., Hu, Z., Schmitz, R., Müller, D., Kostka, M., Brandenburg, T., Xu, H. C., Hardt, C., Vollmer, J., Lang, P. A., & Lang, K. S. (2026). Mutations at Positions 181 and 185 Within the LCMV GP Protein Increase Tumor Cell Infectivity, Limit Induction of Type I Interferon, and Accelerate T Cell Activation. Viruses. https://doi.org/10.3390/v18091002
Vancouver
Bergerhausen M, Holnsteiner L, Friedrich-Becker SK, Hu Z, Schmitz R, Müller D, et al. Mutations at Positions 181 and 185 Within the LCMV GP Protein Increase Tumor Cell Infectivity, Limit Induction of Type I Interferon, and Accelerate T Cell Activation. Viruses. 2026. doi:10.3390/v18091002
BibTeX
@article{Bergerhausen2026,
author = {Bergerhausen, Michael and Holnsteiner, Lisa and Friedrich-Becker, Sarah-Kim and Hu, Zhongwen and Schmitz, Rosa and Müller, Dethardt and Kostka, Marcus and Brandenburg, Tim and Xu, Haifeng C and Hardt, Cornelia and Vollmer, Jörg and Lang, Philipp A and Lang, Karl Sebastian},
title = {Mutations at Positions 181 and 185 Within the LCMV GP Protein Increase Tumor Cell Infectivity, Limit Induction of Type I Interferon, and Accelerate T Cell Activation},
journal = {Viruses},
year = {2026},
doi = {10.3390/v18091002}
}
EUVIMED